Founded in 1876, Eli Lilly reaches its 150th year of scientific innovation on May 11, marking a century and a half of pharmaceutical research and product development. The milestone includes commemorative events and investor briefings to underscore Lilly’s historical breakthroughs in areas such as insulin therapy and oncology.

On May 11, CFO Lucas Montarce will appear live from the NYSE trading floor to analyze Lilly’s latest earnings results, discuss revenue drivers and outline cost management trends. Investors can expect insights into product segment performance and guidance updates for the current fiscal year.

A premium equity research service recently ranked Lilly among top long-term momentum stocks based on proprietary style scores, which assess value, growth and momentum factors. The designation highlights Lilly’s consistent earnings growth, expanding product pipeline and favorable analyst sentiment across multiple performance metrics.